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The safety and efficacy of a new intradermal one dose vaccine containing Porcine Circovirus type 2 (PCV2)
antigen – Porcilis PCV ID – was evaluated in laboratory studies and under field conditions. In addition,
the concurrent use with an intradermalMycoplasma hyopneumoniae vaccine – PorcilisMHyo ID ONCE –
was evaluated.
Vaccination with Porcilis PCV ID resulted in small transient local reactions in a high percentage of the
vaccinated animals with no temperature increase. In both the onset of immunity and duration of immu-
nity challenge studies with PCV2 orM. hyopneumoniae, significant reduction of the PCV2 load in lymphoid
tissue, lungs, serum and fecal swabs and M. hyopneumoniae-induced lung lesions were observed. In two
field trials on two different farms where both PCV2 andM. hyopneumoniaewere present, vaccination with
Porcilis PCV ID and/or Porcilis M Hyo ID ONCE of 3 week old piglets resulted in a significant reduction
of PCV2 viraemia, mortality and lung lesion scores at slaughter. In addition, a significant positive effect on
average daily weight gain (between 44 and 59 g/day) in the finishing phase was observed. The results
support that this new intradermal vaccine is safe and efficacious against PCV2 and may be used
concurrently with Porcilis M Hyo ID ONCE.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Porcine Circovirus type 2 (PCV2) is the causative agent of the
‘‘Post-weaning Multisystemic Wasting Syndrome”, but is also
involved in a number of other disease syndromes which have been
collectively named Porcine Circovirus Diseases (PCVD) [1,2]. The
most pronounced PCVDs are Porcine Respiratory Disease Complex
(PRDC), Porcine Dermatitis and Nephropathy Syndrome (PDNS),
enteritis, reproductive failure, granulomatous enteritis, congenital
tremors and exudative epidermitis. Subclinical PCV2 infections
are characterized by poor growth performance [3–6].
Although intramuscular vaccines against PCV2 [7,8] are rou-
tinely used in the pig industry, no intradermal vaccines have been
available until now. Intradermal (ID) vaccination has the advan-
tage of targeting antigen presenting cells in the epidermis in close
proximity to skin-draining lymph nodes [9,10]. Combined with
needle free administration, ID vaccination is also more animal
friendly and prevents accidental transmission of pathogens caused
by reusing needles as well as broken needles in the muscle. The
objective of the present studies was to evaluate the safety and effi-
cacy under laboratory and field conditions of a new intradermal
vaccine that is based on Porcilis PCV and is named Porcilis PCVID (MSD Animal Health). In addition, concurrent use (at the same
time, but different vaccination sites) with PorcilisMHyo ID ONCE
(MSD Animal Health) was also investigated.2. Materials and methods
2.1. Vaccines
A vaccine containing inactivated, baculovirus-expressed ORF2
antigen of PCV2 and a vaccine containing Mycoplasma hyopneumo-
niae cells, both adjuvanted with an oil-in-water emulsion, Xsolve
(Porcilis PCV ID and Porcilis M Hyo ID ONCE, MSD Animal
Health) were tested. The vaccines were administered with the
IDAL (IntraDermal Administration of Liquids, MSD Animal Health)
injector either alone or concurrently as a single 0.2 ml dose to
3 week old piglets according to the manufacturer’s instructions.2.2. Quality
All laboratory studies and sample testing were conducted in
compliance with GLP, while all field studies were conducted in
compliance with GCP. All laboratory studies were performed after
the approval of the Ethical Committee for Animal Experiments of
MSD Animal Health.
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2.3.1. Laboratory trial
Two groups of healthy SPF pigs were either vaccinated with
Porcilis PCV ID at 19–21 days of age (vaccinated group, N = 20)
or injected with phosphate buffered saline (control group,
N = 10). The piglets were monitored daily for abnormal systemic
and local (by palpating) reactions until 42 days after vaccination.
Body weight was recorded on the day of vaccination, and at 21
and 42 days post vaccination. Rectal temperature was recorded
one day before vaccination, just before vaccination, 4 h after
vaccination and daily for four days. Both at 14 and 28 days
post-vaccination, 5 animals from the vaccinated group were sacri-
ficed for examination of the injection site. The remaining animals
were subjected to the above described procedure at 42 days
post-vaccination.
2.3.2. Field trial
A GCP field safety study was performed according to a con-
trolled, randomized and blinded design in three commercial pig
farms in The Netherlands. In each farm, approximately 90 healthy
18–24 days old piglets were allocated randomly to one of three
groups. The pigs in group 1 (PCV) were vaccinated with Porcilis
PCV ID, the pigs in group 2 (PM) with Porcilis PCV ID and Porcilis
M Hyo ID ONCE concurrently (Porcilis PCV ID in one side of the
neck and Porcilis M Hyo ID ONCE in the other side), the piglets
in group 3 (Control) remained untreated. The piglets were
observed for immediate reactions during or immediately after vac-
cination and general health one day before vaccination, at vaccina-
tion, 1 and 4 h after vaccination and daily for 28 days. The injection
site was examined by palpating for local reactions at 1 and 4 h after
vaccination and daily for 28 days. Rectal temperature was mea-
sured one day before vaccination, just before vaccination, 4 h after
vaccination and daily for 4 days. All study piglets were weighed
individually at admission (day 1) and on day 21.
2.4. Efficacy trials
2.4.1. Vaccination-challenge experiments
The onset of immunity (OOI) and duration of immunity (DOI)
for Porcilis PCV ID (PCV group) alone or Porcilis M Hyo ID ONCE
(M group) alone, and for concurrent use of Porcilis PCV ID and
PorcilisMHyo ID ONCE (PM group) were evaluated in experimen-
tal PCV2 or M. hyopneumoniae challenge studies; the experimental
design of these studies is summarized in Table 1. In each experi-
ment, 3 week old pigs, maternally-derived antibody positive for
PCV2 and free of M. hyopneumoniae, were randomly divided intoTable 1
Experimental design challenge experiments.
Study
type
Group n Challenge material
OOI Porcilis PCV ID 15 PCV2 field isolate
Porcilis PCV ID + Porcilis M Hyo ID
ONCE
15
Unvaccinated control 15
DOI Porcilis PCV ID 20 PCV2 field isolate
Unvaccinated control 20
OOI Porcilis PCV ID + Porcilis M Hyo ID
ONCE
20 M. hyopneumoniae field
isolate
Porcilis M Hyo ID ONCE 20
Unvaccinated control 20
DOI Porcilis PCV ID + Porcilis M Hyo ID
ONCE
40 M. hyopneumoniae field
isolate
Porcilis PCV ID 40groups (PCV, PM, M or control) at the time of vaccination. Blood
samples were taken just before vaccination, between vaccination
and challenge (DOI only), at the time of challenge and 1, 2 (PCV2
challenge studies only) and 3 weeks after challenge. Fecal swabs
(PCV2 challenge studies only) were collected at the time of chal-
lenge and 1, 2 and 3 weeks after challenge.
At 5 (for OOI) or 26 weeks of age (for DOI), pigs were challenged
intranasally (3 ml per nostril, ±106 TCID50) with a recent Dutch
PCV2 field isolate. Three weeks after PCV2 challenge, all pigs were
necropsied and the inguinal lymph nodes, tonsil and lung were col-
lected. Blood samples, fecal swabs and tissue samples were tested
for quantification of the PCV2 viral load by qPCR. In addition the
blood samples were also tested for the presence of PCV2 and M
hyo antibodies.
M. hyopneumoniae challenge was performed at 6 (for OOI) or
25 weeks of age (for DOI) intratracheally on two consecutive days
with 10 ml of a culture of a Danish field isolate (provided by Dr. N.
Friis, National Veterinary Laboratory, Copenhagen) containing
±107 CCU/ml. Three weeks after challenge, the pigs were necrop-
sied to evaluate lung lesions which were scored according to Good-
win & Whittlestone as previously described [11]; the maximum
score is 55.
During the studies, pigs were observed daily for general clinical
abnormalities.
2.4.2. Field trials
Two combined GCP field efficacy and safety studies (studies A
and B) were performed according to a controlled, randomized
and blinded design in two Hungarian pig herds with both an M.
hyopneumoniae and PCV2 infection. Healthy three week old suck-
ling piglets were allocated randomly, within litters, to treatment
groups of approximately 600 (study A) or 330 (study B) piglets
each. The pigs in group one (PCV) were vaccinated intradermally
with Porcilis PCV ID, the piglets in group two (PM) were vacci-
nated intradermally with Porcilis PCV ID and Porcilis M Hyo ID
ONCE concurrently, the piglets in group three (M) were vaccinated
intradermally with PorcilisMHyo ID ONCE (study B only) and the
piglets in group four (control) remained untreated. The primary
efficacy parameters were mortality (study A only), M. hyopneumo-
niae-like lung lesions at slaughter (study B only), PCV2 viraemia
and the average daily weight gain (ADWG) during finishing (i.e.
between 9–10 and 21–23 weeks post vaccination (wpv). Also, sero-
logical response following vaccination or field infection was mea-
sured. The pigs were weighed individually at time of vaccination,
transfer to the finishing unit and just prior to slaughter. Medication
was recorded and pigs that died during the studies were examined
post-mortem to establish the cause of death. Forty (study A) to 60Age at
vaccination
Challenge at . . .
wpv
Samples taken at . . . wpv
Blood samples Fecal swabs
3 weeks 2 0, 2, 3, 4, 5 2, 3, 4, 5
3 weeks 23 0, 7, 17, 21, 22, 23, 24, 25,
26
23, 24, 25,
26
3 weeks 3 0, 2, 6
3 weeks 22 0, 11, 22, 25
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pling approximately every 3 weeks. The normal routine at the farm
of study A included sending the animals to several different
slaughterhouses. This routine did not allow for scoringM. hyopneu-
moniae-like lung lesions, which was therefore not included in the
study design. For study B all M. hyopneumoniae-like lung lesions
were scored at the same slaughterhouse for all piglets. Although
safety was not the primary objective of these studies, animals were
observed at time of vaccination and, as a group, at 4 h after and 1,
4, 7, 14, 21 and 28 days after vaccination.
2.5. Serology
For M. hyopneumoniae, a commercial ELISA (IDEXX, M. hyo Ab
test) was used according to the manufacturer’s instructions.
Results were expressed as negative, positive or inconclusive.
For PCV2, an in-house ELISA was performed as previously
described [12].
2.6. Quantification of PCV2 DNA
Quantification of the PCV2 viral load in serum, lymphoid organs,
lung and fecal swabs were performed by qPCR as previously
described for study 2 [12].
2.7. Statistical analyses
In the lab studies the area under the curve (AUC) of the qPCR
data for the serum samples and fecal swabs collected after PCV2
challenge were calculated by the linear trapezoidal rule and ana-
lyzed by either the Wilcoxon Rank Sum test or the Kruskal Wallis
test. Lung lesion scores in challenge experiments and the qPCR
data of inguinal lymph nodes, lungs and tonsils were also analyzed
by either the Wilcoxon Rank Sum test or the Kruskal Wallis test. In
the field studies, the AUC data were ranked before analysis usingTable 2
Analysis of the safety of the PCV single vaccination (Laboratory safety study).
Number of pigs (n)
Pigs with local reactions (%)
Maximum size of local reactions (cm)
Mean size of local reaction (cm)
Pigs with macroscopically visible local reactions at necropsy (14 days post vaccinatio
Pigs with macroscopically visible local reactions at necropsy (28 days post vaccinatio
Pigs with macroscopically visible local reactions at necropsy (42 days post vaccinatio
Pigs with a systemic reaction (%)
Rectal temperature at 4 h post vaccination (C)
Average daily weight gain (g/day) during the observation period (3–9 week of age)
nt = not tested
* Redness.
Table 3
Analysis of the safety of the PCV single vaccination and concurrent vaccination against M
Number of pigs (n)
Pigs with a deviating general health score (%)
Pigs with local reactions (%)
Maximum size of local reactions (cm)
Rectal temperature at 4 h post vaccination (C)
Average daily weight gain (g/day) during the observation period (3–6 week of age)
a Porcilis PCV ID.
b Porcilis PCV ID + Porcilis M Hyo ID ONCE.
c Vaccinated vs control.
d Porcilis PCV ID/Porcilis M Hyo ID ONCE vaccination site.
e Overall temperature profile (day 1 to day 4).mixed model ANOVA with vaccination group as fixed effect and
production batch as random effect. Mortality was compared
between treatment groups using the Cochran Mantel Haenzel
method with production batch as the classification variable. For
the pairwise comparisons the Genmod procedure (Chi2 test) was
used. Lung lesion scores in the field study were compared between
the groups with a mixed model ANOVA. The average daily weight
gain was compared between the groups via a mixed model ANOVA.
Vaccination group and gender with appropriate interactions were
included as fixed effects and sow and production batch as random
effects. The body weight at admission was included in the model as
a covariate.
3. Results
3.1. Safety studies
3.1.1. Laboratory trial
The results of the safety study using Porcilis PCV ID alone, are
summarized in Table 2. A total of 95% of the animals developed
injection site reactions with an individual maximum andmean size
of 2.8 cm and 1.1 cm, respectively. These local reactions were
biphasic with peaks on day 1 and days 13/14 following vaccination.
Local reactions were never scored as painful. At 14 days post-
vaccination, the subcutaneous adipose tissue appeared thickened
in 3 of the 5 animals necropsied and appeared reddish-brownish
colored in 5 of 5 animals. After 28 days post-vaccination, no injec-
tion site reactions were observed macroscopically at dissection. At
4 h after vaccination, the rectal temperature of vaccinated animals
was comparable with the control animals (p = 0.9252). No systemic
reactions were detected.
3.1.2. Field trials
Results of the safety study, using Porcilis PCV ID alone, or con-
currently with PorcilisMHyo ID ONCE are summarized in Table 3.Porcilis PCV ID Control p-Values
20 10
95 10* <0.001
2.8 0
1.14 0
n) (%) 100 nt
n) (%) 0 nt
n) (%) 0 0
0 0
39.7 ± 0.3 39.7 ± 0.2 0.9252
460 443 0.6835
. hyopneumoniae (Field safety study).
PCVa PMb Control p-Valuesc
90 87 87
4 5 3
93 92/95d 10 <0.001
3 3 0.5
39.8 ± 0.4 39.9 ± 0.4 39.8 ± 0.3 0.1241e
219 ± 9 212 ± 9 214 ± 9 0.5199
Fig. 1. Mean group anti-PCV2 antibody responses and mean PCV2 DNA load in sera, fecal swabs and tissue samples at necropsy in PCV2 challenge studies. Pigs were infected
at 2 or 23 weeks post vaccination.
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Fig. 2. Group anti-M. hyopneumoniae seroresponse rates and median lung lesion scores at necropsy in M. hyopneumoniae challenge studies. Pigs were infected at 3 or
22 weeks post vaccination.
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observed. A deviation in general health was occasionally observed
in all groups with no differences in the frequency between the vac-
cinated groups (PCV and PM) and the control group.
Up to 93–95% of the animals, in both the single and concurrent
group, developed local reactions. The large majority of animals
with local reactions (>74%) were 61 cm and the largest reaction
observed, <2% of the reactions measured, were 3.0 cm. Local reac-
tions disappeared around day 21–28 for the majority (>76%) of the
animals in both groups. All had disappeared 50 days after vaccina-
tion. Local reactions were never scored as painful. The mean tem-
perature profiles (p = 0.1241) and the ADWG (p = 0.5199) were not
significantly different between treatment groups.
In the field efficacy and safety study A no local reactions were
observed. The maximum incidence of local reactions caused by
Porcilis PCV ID was observed 14 days pv in study B: 2% in the
PCV and 8% in the PM group. The maximum incidence of local reac-
tions caused by Porcilis M Hyo ID ONCE was observed 21 days pv
in study B: 11% in the PM group and 8% in the M group. The max-
imum size of the local reactions in the PCV group were 3 cm, in the
PM group 4 cm (Porcilis PCV ID side) and 6 cm (PorcilisMHyo ID
ONCE side), and in the M group 4 cm.3.2. Vaccination-challenge experiments
No clinical abnormalities that could be related to treatment
were observed in the periods between vaccination and challenge.
However, in the PCV2 OOI study one vaccinated pig in the PM
group was found lame during the study and as a result the animal
was euthanized for animal welfare reasons.
Although clinical signs were not observed following PCV2 chal-
lenge, qPCR data of the various samples confirmed infection(Fig. 1). Mean viral loads in lymphoid tissues and lung were in
general between 3 and 4log10 lower in the vaccinated pigs, and
the differences between the groups were statistically significant
(p < 0.05). Compared to the control animals, the viral load of the
vaccinated animals (log10 transformed, calculated as AUC) was
significantly reduced by 70–100% in serum and 81–100% in fecal
swabs (p < 0.05). Following vaccination, a clear antibody response
against PCV2 was observed, as shown by an increase in antibody
titer in the PCV2 OOI study followed by a slower decline resulting
in average titers of around 4.0log2, compared to the control group,
in the PCV2 DOI study.
In contrast, the control pigs in the DOI study had declining
maternal antibody titers and remained serologically negative until
the time of challenge. Following challenge, vaccinates developed
an anamnestic response and the animals in the control group
started to seroconvert. The antibody titers between vaccinated
and control groups were significantly different from the time of
vaccination onwards, until the time of necropsy.
In the M. hyopneumoniae challenge experiments, almost all the
control animals seroconverted to the challenge infection (Fig. 2). At
necropsy, 3 weeks post challenge, the median M. hyopneumoniae-
induced lung lesions in the vaccinated groups were significantly
reduced by 92–100% (OOI study) and 77% (DOI study) compared
to the controls (p < 0.05).3.3. Field efficacy studies
The PCV2 serological profiles of the pigs in both field studies
(A and B) (Fig. 3) are indicative of a PCV2 infection in both studies,
which was confirmed by the detection of PCV2 at low amounts in
the control animals at 10 wpv and 4 wpv, respectively. Compared
to the control animals the viral load in serum of the vaccinated
Fig. 3. Mean group anti-PCV2 antibody responses and mean PCV2 DNA load in sera, fecal swabs in the field efficacy studies. The corresponding mean areas under the curve
(AUC) are presented below in the individual panels.
Table 4
Descriptive data of study animals and performance in PCV2-M. hyopneumoniae field efficacy study A.
Age (weeks) PCV PM Control Difference p-Valuea p-Valueb
PCV-control PM-control
Number of pigs for mortality (n) Study inclusion 606 602 602
Number of pigs for ADWG (n) 314 313 313
Mortality (%) 3–13 6 7 8 2 1 0.1407
13–24 3 2 5 2 3 0.0110 0.0001
3–24 9 9 14 5 5 0.0004 0.0020
ADWG (g/day) 3–13 328 ± 10d 331 ± 10 330 ± 10 2 +1 0.8369c
13–24 768 ± 22 775 ± 22 724 ± 22 +44 +51 <0.0001 <0.0001
3–24 569 ± 9 573 ± 9 544 ± 9 +25 +29 <0.0001 <0.0001
a PCV (Porcilis PCV ID group) vs control group.
b PM (Porcilis PCV ID + Porcilis M Hyo ID ONCE group) vs control group.
c Overall analysis using mixed model ANOVA.
d Mean ADWG adjusted for litter, sex, batch and weight at admission ± standard error of the mean.
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and >88% (B) (p < 0.05).
Vaccination with Porcilis PCV ID induced more than 44 g
higher ADWG during finishing (p < 0.0001) and more than 25 g
higher ADWG during the entire study period (p < 0.0001) than in
the control animals (Tables 4 and 5). Concurrent vaccination with
Porcilis M Hyo ID ONCE induced over 51 g and over 29 g higher
ADWG during finishing and during the entire study period respec-
tively (p < 0.05). Vaccination with Porcilis M Hyo ID ONCE did not
result in an increase in ADWG.
In study A, where mortality was a primary parameter, mortality
was significantly reduced by 5% in the vaccinated groups, com-
pared to the controls (PCV p = 0.0004; PM p = 0.0020).
In study B, whereM. hyopneumoniae-like lung lesions at slaugh-
ter were a primary parameter, the lesions were significantlyreduced (p < 0.0001) in the PM and M vaccinated group, compared
to the controls and the PCV vaccinated group (see Fig. 4).4. Discussion
Porcilis PCV ID was developed specifically for intradermal
administration using a needle free and intradermal injector such
as the IDAL. The needle free administration improves animal health
and food safety as there is no risk of needle breakage or transmis-
sion of disease by re-use of needles. The IDAL allows for a dose vol-
ume of 0.2 ml, which is one tenth of the volume of Porcilis PCV,
the intramuscular vaccine on which Porcilis PCV ID is based. Com-
pared to intramuscular injection, vaccination into the dermis has
the advantage of the presence of dendritic cells at the site of
Table 5
Descriptive data of study animals and performance in PCV2-M. hyopneumoniae field efficacy study B.
Age (weeks) PCV PM M Control Difference p-Valuea p-Valueb p-Valuec
PCV-control PM-control M-control
Number of pigs (n) Study inclusion 280 281 326 329
Mortality (%) 3–13 4 3 5 3 +1 0 +2 0.7591d
13–24 4 2 6 8 4 6 2 0.2904 0.0315 0.2259
3–24 8 5 10 11 3 6 1 0.0536d
ADWG (g/day) 3–13 392 ± 8e 403 ± 8 380 ± 7 383 ± 7 +9 +20 2 0.1292 0.0006 0.509
13–24 795 ± 11 805 ± 11 758 ± 11 746 ± 11 +49 +59 +12 <0.0001 <0.0001 0.2166
3–24 637 ± 7 648 ± 7 613 ± 7 607 ± 7 +30 +41 +6 <0.0001 <0.0001 0.3536
Mean lung lesion score 20–27 6.4 ± 8 3.4 ± 6 4.2 ± 7 7.7 ± 9 1.2 4.3 3.5 0.1733 <0.0001 <0.0001
a PCV (Porcilis PCV ID group) vs control group.
b PM (Porcilis PCV ID + Porcilis M Hyo ID ONCE group) vs control group.
c M (Porcilis M Hyo ID ONCE group) vs control group.
d Overall analysis using Chi2 test.
e Mean ADWG adjusted for litter, sex, batch and weight at admission ± standard error of the mean.
Fig. 4. Group anti-M. hyopneumoniae seroresponse rates, mean lung lesion scores at slaughter and lesion score distribution in the field efficacy studies.
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nodes, resulting in a direct response to the antigen in the vaccine.
Therefore, the adjuvant and/or antigen concentration of an intra-
dermal vaccine can be lower to achieve a comparable or even more
effective efficacy [13]. In the case of Porcilis PCV ID the adjuvant is
only approximately 25% of that of Porcilis PCV and still induces
both a good immune response and no severe local reactions.
The presented results support that the new intradermal PCV2
vaccine can safely be administered to 3 week old piglets. The local
reactions seen in the present studies, although common,were small,
transient and never painful. Local reactions were observed com-
monly when palpating individual animals, but rarely, probably
due to their small size,whenonly observing animals fromadistance.
The experimental challenge studies indicate that the onset of
immunity against PCV2 infection occurs as early as 2 weeks post-
vaccination and lasts for at least 23 weeks. Following vaccination
in the PCV2 DOI study, a decline in PCV2 antibody titer was mea-
sured until 17 wpv after which the titers remained level at
4.0log2 until the end of the study. Although this is a relatively
low mean titer, the results after challenge show that the animals
were still protected against PCV2, which could also be suggestive
of the induction of cellular immunity by intradermal vaccination
[9]. Accordingly, a single vaccination of animals at 3 weeks of age
may protect fattening pigs against PCV2 infections during the pro-
duction life cycle. In addition the challenge studies indicate that
Porcilis PCV ID can be given concurrently (at the same time but
at different vaccination sites) with Porcilis M Hyo ID ONCE, as
demonstrated by comparable results between single and concur-
rent vaccination. Concurrent vaccination is both user and animal
friendly as the animals only need to be handled once to protect
against two major swine pathogens.
The results obtained during the challenge experiments were
confirmed in the field efficacy trials in the presence of PCV2 and
M. hyopneumoniae infections: strong reductions in PCV2 viral load
and M. hyopneumoniae-like lung lesions were measured, resulting
in reduced mortality and weight loss. This is in line with what
has been observed with intramuscular PCV2 and/orM. hyopneumo-
niae vaccines (Porcilis PCV, Porcilis PCV M Hyo) [14,15].
In the field efficacy trial B, Porcilis M Hyo ID ONCE improved
the ADWG with 12 g/day compared to the controls. This result
did not reach statistical significance and is contrary to previous
results [16]. A possible explanation could be the late onset of the
M. hyopneumoniae infection as evidenced by the absence of a
serum response in the control group until 20 wpv. Under the con-
ditions of this farm, the highest reduction of weight loss was mea-
sured when concurrently vaccinating with Porcilis PCV ID and
Porcilis M Hyo ID ONCE, supporting the importance of addressing
both PCV2 andM. hyopneumoniae infections when present simulta-
neously in a farm.
In conclusion, the study results support that a one-dose PCV2
vaccine administered intradermally with a needle free injector issafe and provides protection until at least 23 weeks post vaccina-
tion, which is a typical slaughter age.
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